Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joon Lee - Truist Salim Syed - Mizuho Luca Issi - RBC Catherine Novack - Jones Trading Madison El-Saadi - B. Riley Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other j ...

Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that of er first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Wave Life Sciences (WVE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Novem ...

Wave Life Sciences (WVE) closed the last trading session at $14.45, gaining 74.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.44 indicates a 34.5% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $2.70. While the lowest estimate of $15 indicates a 3.8% increase from the current price level, the most optimistic analyst ...

This stock currently has a good balance of risk and potential rewards.With its shares skyrocketing by upwards of 74% on Oct. 16, Wave Life Sciences (WVE -1.08%) is now on the map of many investors. Per an update from one of its early-stage clinical trials, it just marked a first-in-humans scientific milestone. That cleared the way for its stock to continue gaining value as the biotech builds on its preliminary results.So what exactly did this company accomplish, and how important is it going to be in the lo ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

文章核心观点 - Wave Life Sciences是一家专注于RNA编辑技术的生物技术公司,正在开发一系列针对遗传疾病的RNA编辑疗法 [1][2] - 公司最近取得了首次在人体中进行RNA编辑的重大突破,这为其在RNA编辑领域的地位奠定了基础 [2][3] - 公司的RNA编辑技术有望彻底改变遗传疾病的治疗方式,引起了投资者和分析师的广泛关注 [1][2][3] - 尽管公司目前仍处于临床试验阶段,但分析师普遍看好其长期发展前景,纷纷上调了对公司股票的评级和目标价格 [4][5][6][7][8] 根据目录分别总结 公司概况 - Wave Life Sciences是一家专注于RNA编辑技术的生物技术公司,致力于开发可以改变人类健康的RNA药物 [1] - 公司是RNA编辑技术领域的先驱之一,其创新精神吸引了投资者和科学界的广泛关注 [1] 重大突破 - 公司最近在AATD(α-1抗胰蛋白酶缺乏症)治疗中取得了首次在人体中进行RNA编辑的重大突破 [2][3] - 这一成果巩固了公司在RNA编辑领域的先驱地位,为其未来发展奠定了基础 [2][3] 财务表现 - 公司目前仍处于临床试验阶段,财务表现反映了大量的研发投入,存在一定亏损 [4][5] - 但分析师普遍看好公司的长期发展前景,预计随着管线项目的推进,收益和盈利能力将逐步改善 [4][5] 市场反应 - 公司的重大突破引发了市场的广泛关注,多家券商纷纷上调了对公司股票的评级和目标价格 [6][7][8] - 分析师普遍认为公司有望成为RNA编辑技术领域的领导者,但投资者仍需谨慎,因为产品最终能否成功尚存在不确定性 [9][10]

Shares of Wave Life Sciences (WVE) surged 74.1% on Wednesday after the company reported positive proofof-mechanism data from an ongoing early to mid-stage study of its investigational candidate, WVE-006, for alpha-1 antitrypsin deficiency (AATD), a type of genetic disorder. WVE-006 is a GalNAc-conjugated oligonucleotide that enables A-to-I RNA editing and is administered subcutaneously. Developed with Wave Life Sciences' advanced oligonucleotide chemistry platform, it is specifically designed to target lung ...

Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 49.9% gain over the past four weeks. The sudden rise in the stock price was observed after the company announced positive proof-of-mechanism data, showing first-ever therapeutic RNA editing in humans, from the first single-dose cohort (200 mg) of the phase Ib/IIa Restor ...